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A B S T R A C T
The use and need for follow-up of cardiac electronic implantable devices, such as 
pacemakers and implantable defibrillators, is constantly increasing, and constitutes 
an ever-growing burden and cost in clinical practice and the health system in general. 
Telemedicine or remote, wireless home monitoring (HM) has recently come to aid in 
this situation and reliably retrieve information on the patient`s and device`s status and 
transmit it to the implanting center and physician. It thus offers considerable conve-
nience and assurance to both patient and physician. To date this technology of remote 
monitoring allows continuous and episode related arrhythmia monitoring as well as 
continuous monitoring of the status of the implanted system (battery status, lead im-
pedance). Preliminary data from ongoing large multicenter studies are promising and 
relate to the diagnostic power of telemetrically transmitted data, necessity for patient 
follow up, the influence of HM on the optimisation of device and medical therapy, and 
the impact of HM on cost- effectiveness in device therapy.
I N T R O D U C T I O N
In contemporary cardiology the use of highly sophisticated implantable devices, 
such as pacemakers (PM) and implantable cardioverter defibrillators (ICD), is increas-
ing, constituting an ever-growing burden on both clinical routine and costs. Due to 
the technological complexity of these devices and their use in critically ill patients 
regularly scheduled follow -up visits are mandatory to obtain information on both 
device status and performance. On top of these regularly scheduled clinical visits, 
event related visits further increase the burden to the health system.
C U R R E N T  D E V I C E  F O L L O W - U P  S C H E M E
The currently used follow-up scheme has some marked disadvantages: 1) many 
follow-up procedures are performed routinely only not requiring any change in device 
or drug therapy, 2) programmer based tests are performed under artificial conditions 
not reflecting real life, 3) asymptomatic arrhythmia episodes or changes in the ar-
rhythmia pattern are hidden until the next regular follow up is performed, 4) there is 
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no direct feed back on the efficiency or adverse effects of the 
device therapy, and 5) early indicators for potential device 
failure in the near future are of reduced or no value.
W I R E L E S S  R E M O T E  H O M E 
M O N I T O R I N G
To overcome the drawbacks of the current scheme the 
idea of telemedicine or home monitoring (HM) has come 
up which would allow to reliably retrieve information on the 
patient`s and device`s status although analyser and patient 
are distant from each other.1-9 To date this technology allows 
continuous and episode related arrhythmia monitoring as 
well as continuous monitoring of the status of the implanted 
system (battery status, lead impedance). Future perspectives 
include monitoring of vital cardiovascular parameters and 
bidirectional telemetry i.e. telemetrically reprogramming of 
the device. The possible advantages of HM include a close 
medical supervision of improved quality, monitoring of success 
and adverse effects of device therapies with increased resolu-
tion and documentation of complications. Thus the follow 
up scheme probably may be individualized for the patients 
reducing the overall burden on the health system.
Figure 1 graphically shows the HM system. The implanted 
device automatically transmits data from the device memory 
over a distance of several meters using unidirectional long-
range telemetry, i.e. without the need of a programmer head. 
The data is transmitted to a patient device that is placed a few 
meters away from the patient, and this device forwards the 
data via mobile phone technology to the BIOTRONIK Service 
Centre. This transmission happens in an automatic, periodic or 
event triggered manner. Pacemaker messages may also be pa-
tient triggered via application of a magnet. The data received 
by the BIOTRONIK Service Centre is gathered, presented in 
graphs and tables as a Cardio Report and forwarded to the 
physician via fax or e-mail in the intervals he/she specifies. 
The intervals can be chosen to be patient specific and can 
easily and instantaneously be adapted to the physician`s actual 
needs. Furthermore, the sending of a Cardio Report can also 
be triggered by event criteria, i.e. a Cardio Report goes out 
to the physician whenever the incoming data fulfils certain 
criteria specified in advance by the physician.
Figures 2 a+b show an example of a Cardio Report gener-
ated by the BIOTRONIK dual chamber PM “Philos DR-T”. 
Information is given on the intrinsic and stimulated heart 
rhythm, AV conduction and battery and lead status. Figure 
3 shows an example of a Cardio Report generated by the 
BIOTRONIK single chamber ICD “Belos VR-T”. Episode 
data report the number of episodes detected in the different 
tachycardia zones, therapy data report the number of anti-
tachycardia pacing episodes/shocks that have been delivered 
and the proportion of success and system data give information 
on the battery and lead status.
M U L T I C E N T E R  S T U D I E S
There are 2 ongoing international multicenter studies 
(Philos DR-T and Belos VR-T) that investigate the diagnostic 
power of telemetrically transmitted data with regard to the 
necessity for patient follow up, the influence of HM on the 
optimisation of device therapy and additional medication, 
the acceptance of HM by the implanted patient and last but 
not least the impact of HM on cost- effectiveness in device 
therapy. Preliminary analysis shows that 100% of messages 
were correctly transmitted and that 97% of all messages reach 
the Service Centre in less than 3 minutes. So far it can be 
concluded that the technology for mobile seamless monitoring 
is available and the technical feasibility is proven. It appears 
that HM indeed does enhance PM and ICD diagnostics by au-
tomatic monitoring with 24 hour resolution and event related 
reporting. Extrapolated from retrospective data obtained at 
our own institution it may be anticipated that HM is cost ef-
fective. Between 1990 and 2003 a total of 627 patients received 
an ICD. During this period a total of 10.634 follow up visits 
was performed of which in only 23.2 percent one or the other 
action had to be done. Given the cost of 139 € per follow up a 
total amount of 1.140.999,0 € could have been saved had HM 
been available.
In summary, HM is technically available and feasible. 
Preliminary data from ongoing large international multicenter 
studies are promising. Recent analysis of a world-wide data-FIGURE 1
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base of HM supports its capability to improve patient care and 
safety, and optimize the allocation of health resources.7
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